Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: a histologic and immunohistochemistry analysis

Abstract

The advent of targeted therapies using BRAF or MEK inhibitors (BRAFi or MEKi) or their combinations (BiMiC) as well as checkpoint immunotherapies based on antibodies to CTLA4 or PD1 has recently brought about a drastic revolution in the treatment of advanced cancers, in particular of melanoma. These therapies are, however, not without side effects. Many of them involve the skin and range from keratosis to squamous cell carcinomas under BRAFi monotherapy and from lichenoid reactions to vitiligo under immunotherapies.

This article is protected by copyright. All rights reserved.